Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of -$0.04 Per Share

Brokerages expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report ($0.04) earnings per share for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Enanta Pharmaceuticals’ earnings. The highest EPS estimate is $0.11 and the lowest is ($0.27). Enanta Pharmaceuticals reported earnings of $0.97 per share during the same quarter last year, which would indicate a negative year over year growth rate of 104.1%. The company is expected to report its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Enanta Pharmaceuticals will report full year earnings of $1.53 per share for the current financial year, with EPS estimates ranging from $0.81 to $2.00. For the next year, analysts expect that the business will post earnings of ($0.60) per share, with EPS estimates ranging from ($1.64) to $0.06. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.29. Enanta Pharmaceuticals had a return on equity of 19.25% and a net margin of 33.28%. The company had revenue of $39.60 million during the quarter, compared to analysts’ expectations of $40.92 million. During the same quarter in the previous year, the business earned $0.61 EPS. Enanta Pharmaceuticals’s revenue was down 10.0% compared to the same quarter last year.

A number of equities analysts recently issued reports on ENTA shares. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a report on Friday, May 10th. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Finally, Berenberg Bank upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $80.00 to $120.00 in a report on Tuesday, April 23rd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $114.40.

In related news, VP Yat Sun Or sold 10,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $103.53, for a total transaction of $1,035,300.00. Following the completion of the transaction, the vice president now owns 304,763 shares in the company, valued at approximately $31,552,113.39. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bruce L. A. Carter sold 1,546 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $99.16, for a total value of $153,301.36. Following the transaction, the director now owns 1,546 shares of the company’s stock, valued at approximately $153,301.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,826 shares of company stock valued at $2,150,473. 11.35% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of ENTA. Vanguard Group Inc lifted its holdings in shares of Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after buying an additional 330,374 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 30.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock worth $121,934,000 after buying an additional 330,374 shares during the period. Marshall Wace North America L.P. lifted its holdings in shares of Enanta Pharmaceuticals by 1,128.7% in the 1st quarter. Marshall Wace North America L.P. now owns 225,694 shares of the biotechnology company’s stock worth $21,558,000 after buying an additional 207,326 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Enanta Pharmaceuticals by 17.0% in the 1st quarter. Janus Henderson Group PLC now owns 874,397 shares of the biotechnology company’s stock worth $83,522,000 after buying an additional 126,804 shares during the period. Finally, Norges Bank purchased a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth $7,106,000. Institutional investors and hedge funds own 86.86% of the company’s stock.

ENTA traded down $1.56 during trading hours on Tuesday, reaching $90.01. 122,097 shares of the company’s stock traded hands, compared to its average volume of 170,330. Enanta Pharmaceuticals has a 52-week low of $64.08 and a 52-week high of $127.77. The stock has a market cap of $1.77 billion, a P/E ratio of 25.86 and a beta of 1.30.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.